Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) | RFA MD 18 010

Opportunity Information: Apply for RFA MD 18 010

The Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42 - Clinical Trial Optional) opportunity, listed as RFA-MD-18-010, is a National Institutes of Health (NIH) funding announcement designed specifically for U.S. small businesses that want to translate research into practical, market-ready solutions that improve minority health and reduce health disparities. The program uses the Small Business Technology Transfer (STTR) mechanism, which is built around a formal partnership between a small business concern (SBC) and a nonprofit research institution. In plain terms, it is meant to help a small company and a research partner jointly develop a technology that can realistically be commercialized and adopted in the real world, rather than staying at the proof-of-concept stage.

The core goal of the announcement is to support the development of a product, process, or service that helps address documented health gaps affecting NIH-defined health disparity population groups. While the notice does not list every population group in the excerpt provided, the intent is clear: the proposed technology should target conditions and outcomes where disparities exist, and it should do so in a way that is not only scientifically sound but also practical for the communities most affected. NIH emphasizes that the technologies should be effective, affordable, and culturally acceptable, which is an important signal that reviewers will likely look beyond technical performance alone. They will care about whether the solution can be used and trusted by the intended population, whether it fits real-life constraints like cost and access, and whether it is designed in a way that respects language, norms, and lived experience.

This opportunity falls under the NIH grant category and is associated with CFDA number 93.307, indicating it is part of the NIH portfolio focused on minority health and health disparities. The activity uses the R41/R42 STTR phases: typically, R41 (Phase I) supports early feasibility work and prototype development, while R42 (Phase II) supports more advanced development such as refinement, validation, and preparation for commercialization. The announcement notes "Clinical Trial Optional," meaning applicants may propose a project that includes a clinical trial if it is appropriate for the technology and stage of development, but they are not required to do so. This flexibility matters because some technologies may need human testing to demonstrate impact, while others may be better suited to laboratory validation, simulation, usability studies, or implementation-focused work before moving into clinical trials.

Eligibility is limited to U.S. small business concerns as the primary applicants. Foreign institutions are explicitly not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply as components of the applicant organization. However, the announcement leaves room for "foreign components" as defined under the NIH Grants Policy Statement, which generally means certain discrete project elements may be conducted outside the U.S. if they are strongly justified and meet NIH policy requirements. Practically, most applicants should plan for the major work and leadership to be U.S.-based and should treat any international involvement as exceptional and tightly justified rather than routine.

From a competitiveness standpoint, the emphasis on commercialization is not just a buzzword. Applicants should be prepared to explain why the proposed technology has a real path to adoption: who will use it, who will pay for it, how it fits into existing care workflows or public health systems, what the regulatory or compliance pathway looks like (if relevant), and what makes it sustainable beyond the grant period. Because the target is minority health and disparity reduction, strong applications would typically show a clear connection between the technology and a specific disparity (for example, reduced access, lower screening rates, higher complication rates, or poorer treatment adherence) and then explain how the technology measurably improves outcomes in that context. Affordability and cultural acceptability are also practical design requirements, not afterthoughts, so applicants would generally be expected to show evidence of community input, user-centered design, language access planning, and consideration of the settings where the tool will actually be deployed (such as community clinics, rural practices, safety-net hospitals, schools, faith-based settings, or home use).

Administrative details in the source information indicate the opportunity was created on 2018-08-01 with an original closing date of 2019-04-01. The listing identifies NIH as the agency and "Health" as the funding activity category. Some fields like the award ceiling, expected awards, and the number of awards are not specified in the excerpt, so an applicant would normally confirm budget limits and other constraints in the full FOA text. Even without those specifics, the overall structure is clear: it is an NIH STTR grant opportunity intended to move technologies from research toward real-world products and services that can help close persistent gaps in health outcomes for disparity-affected populations in the United States.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.307.
• This funding opportunity was created on 2018-08-01.
• Applicants must submit their applications by 2019-04-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for RFA MD 18 010

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: